Abstract
BackgroundPancreatic ductal adenocarcinoma (PDAC) is an aggressive, poorly immunogenic cancer that is increasing in incidence. PDAC tumors are highly refractory to all currently available treatments including existing immune checkpoint blockade...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have